ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

リファマイシン

Rifamycin

HCID 6324616
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
6998-60-3
標準SMILES
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
InChIKey
HJYYPODYNSCCOU-ODRIEIDWSA-N
分子式
C37H47NO12
平均分子量
697.8 g/mol
単同位体質量
697.30982593

概要

Rifamycin SV is a member of the class of rifamycins that exhibits antibiotic and antitubercular properties. It has a role as an antitubercular agent, an antimicrobial agent and a bacterial metabolite. It is a lactam, a polyphenol, a member of rifamycins, an organic heterotetracyclic compound, an acetate ester, a macrocycle and a cyclic ketal. It is a conjugate acid of a rifamycin SV(1-).

名称と識別子

優先名称
Rifamycin
IUPAC
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
現地名
リファマイシン
英語名
RIFAMYCIN SV
分子式
C37H47NO12
分子量
697.77

名称と別名

RIFAMYCINRifamycin SVRifamicine SVRifomycin SVRifamicinaRifamycine6998-60-3RifamycinumRifocynRIFOMYCINDU69T8ZZPADTXSID1032014
名称をさらに表示
リファマイシンSVリホシンリファマイシン(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-ペンタヒドロキシ-11-メトキシ-3,7,12,14,16,18,22-ヘプタメチル-6,23-ジオキソ-8,30-ジオキサ-24-アザテトラシクロ[23.3.1.14,7.05,28]トリアコンタ-1,3,5(28),9,19,21,25(29),26-オクタエン-13-イル アセタートrifocinrifamicinesvRIFAMYCIN INNRifamycin S-NaRifamycin (9CI)RIFAMYCIN SV USP/EP/BPRifaximin EP Impurity CRifaximin impurity C (EP)
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetateCHEBI:29673Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other meansRifamycine Chibret5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate((7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.14,7.05,28)triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl) acetate(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.1^(4,7).0^(5,28))triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate

物性

構造計算による物性補完中

XLogP
4.9
極性表面積
201 Ų
水素結合供与体数
6
水素結合受容体数
12
回転可能結合数
3
重原子数
50
形式電荷
0
複雑度
1,330

実験および物理化学的性質

LipidsPolyketides [PK] -> Ansamycins and related polyketides [PK05]
SolubilityInsoluble
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Gastrointestinal Agents; Rifamycins
Endocrine DisruptorsPotential endocrine disrupting compound
Dissociation Constants1.8

物理化学的性質

融点
300 ° · 300° (dec 140°)
比旋光度
20 · D20 -4° (methanol)
沸点
701.9 °C · 701.9°C (rough estimate)
比重(密度)
1.2275 · 1.2275 (rough estimate)
屈折率
1.535 · 1.5350 (estimate)
酸解離定数(Pka)
5.17 · 5.17±0.70(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Other Safety InformationIMAP assessments - Rifamycin: Environment tier I assessment

毒性情報

Hepatotoxicity · 1 件

In prelicensure controlled trials in patients with traveler’s diarrhea, rates of serum ALT elevations were similar in subjects treated with rifamycin compared to placebo or comparator agent (ciprofloxacin) and no participants developed clinically apparent liver injury. Since its approval, there have been no published reports of hepatotoxicity attributed to rifamycin. Because of its minimal absorption rifamycin is considered unlikely to cause liver injury.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

毒性
LD50 in mice (mg/kg): 550 i.v.; 625 i.p.; 2120 orally (Bergamini, Fowst)

化学と産業

薬理情報

ATC Code · 6 件

J04AB03

A - Alimentary tract and metabolism

S - Sensory organs

S - Sensory organs

J - Antiinfectives for systemic use

D - Dermatologicals

Protein BindingThe protein binding of rifamycin is of about 80-95%.
Pharmacodynamics · 1 件

Rifamycin is known to be effective against Gram-positive and Gram-negative pathogens and mycobacteria. It is very effective against _E. coli_ reporting a MIC90 of 64-128 mcg/ml without showing cross-resistance with other antimicrobial agents. The specific indication of rifamycin is extremely important as ther were previous reports that indicated a high risk factor in the generation of resistant _E. coli_ strains in patients with inflammatory bowel disease. In clinical trials, rifamycin was tested in a randomized clinical trial of travellers' coming from Mexico and Guatemala. In this trial, rifamycin was proven to significantly reduce the symptoms of travellers' diarrhea.

Mechanism of Action · 1 件

Rifamycins, as well as all the other members of this group, present an antibacterial mechanism of action related to the inhibition of RNA synthesis. This mechanism of action is done by the strong binding to the DNA-dependent RNA polymerase of prokaryotes. The inhibition of the RNA synthesis is thought to be related with the initiation phase of the process and to involve stacking interactions between the naphthalene ring and the aromatic moiety in the polymerase. As well, it has been suggested that the presence of zinc atoms in the polymerase allows for the binding of phenolic -OH groups of the naphthalene ring. In eukaryotic cells, the binding is significantly reduced making them at least 100 to 10,000 times less sensitive to the action of rifamycins. The members of the rifamycin family present the same mechanism of action and the structural modifications are usually related to pharmacokinetic properties as well as to the interaction with eukaryotic cells.

Biological Half-LifeThe reported half-life when a dose of 250 mg of rifamycin was administered is 3 h.

関連反応

4 件
反応記録を作成
HRID 46717 の反応式
HRID 46717反応物として
HRID 1388495 の反応式
HRID 1388495生成物として
HRID 1388496 の反応式
HRID 1388496生成物として
HRID 1415408 の反応式
HRID 1415408生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
6998-60-3
PubChem CID
6324616
DTXSID
DTXSID1032014
ChEMBL
CHEMBL437765
ChEBI
CHEBI:29673
UNII
DU69T8ZZPA
EC Number
230-273-3
Metabolism/Metabolites
When absorbed, rifamycin is mainly metabolzied in hepatocytes and intestinal microsomes to a 25-deacetyl metabolite.
FDA Pharmacological Classification · 5 件

DU69T8ZZPA

RIFAMYCIN

Established Pharmacologic Class [EPC] - Rifamycin Antibacterial

Chemical Structure [CS] - Rifamycins

Rifamycin is a Rifamycin Antibacterial.

MeSH Pharmacological Classification · 2 件

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and Excretion · 4 件

Rifamycin has a very poor absorption and thus, the generation of an oral modified-release formulation using the technology of the multi-matrix structure was required for the generation of the FDA approved product. This preparation allows the delivery of the active ingredient in the distal small bowel and colon without interfering with the flora in the upper gastrointestinal tract. The multi-matrix is made by a lipophiic matrix surrounded in a hydrophilic matrix which allows for the protection of the active ingredient from dissolution in the intestinal aqueous fluids before it arrives in the cecum. All this matrix is surrounded by a gastro-resistant polymer that only desintegrate in a pH lower than 7. All this administration-customed formulation allows for a bioavailability of <0.1% and the plasma concentrations are reported to be of <2 ng/ml in patients receiving a dose of 400 mg. This confirms that the site of action of rifamycin stays in the small intestine and colon which prevents the need for dose adjustments in special populations as well as systemic drug interactions. The reported Cmax, tmax, AUC and mean residence time after a dosage of 250 mg of rifamycin is 36 mg/L, 5 min, 11.84 mg.h/L and 0.49 h respectively.

From the administered dose, 18%, 50% and 21% is recovered in feces during the first 24, 48 and 72h after administration. This will represent about 90% of the administered dose eliminated by the feces while the urinary secretion is negligible.

The reported volume of distribution after measured after a dosage of 250 mg of rifamycin is 101.8 L.

The reported clearance when a dose of 250 mg of rifamycin was administered is 23.3 L/h.

応用分野 · 1 件

使用Rifogal (Rifaximin EP Impurity C NA) is a antibacterial drug which functions by inhibiting bacterial RNA polymerase (RNAP), is an important part of the antibacteral armamentarium. Also, it is one of the few drugs in a multidrug regimens for treating lung disease (LD) due to Mycobacterium avium complex (MAC).

調製方法 · 1 件

純化方法Rifamycin SV gives yellow-orange crystals from Et2O/pet ether or aqueous EtOH, is very soluble in MeOH, EtOH, Me2CO and EtOAc, and is less soluble in Et2O and HCO3-, but slightly soluble in H2O and pet ether. Its UV has max at 223, 314 and 445nm ( 1cm 586, 322 and 204) in phosphatebuffer pH 7. [NMR: Bergamini & Fowst Arzneim.-Forsch 15 951 1965.]

上流・下流製品情報

下流製品

リファマイシンSVナトリウム塩

補足説明

定義ChEBI: A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.